1.Diverging Relationships among Amyloid, Tau, and Brain Atrophy in Early-Onset and Late-Onset Alzheimer’s Disease
Han Kyu NA ; Jeong-Hyeon SHIN ; Sung-Woo KIM ; Seongho SEO ; Woo-Ram KIM ; Jae Myeong KANG ; Sang-Yoon LEE ; Jaelim CHO ; Justin BYUN ; Nobuyuki OKAMURA ; Joon-Kyung SEONG ; Young NOH
Yonsei Medical Journal 2024;65(8):434-447
Purpose:
Alzheimer’s disease (AD) dementia may not be a single disease entity. Early-onset AD (EOAD) and late-onset AD (LOAD) have been united under the same eponym of AD until now, but disentangling the heterogeneity according to the age of sonset has been a major tenet in the field of AD research.
Materials and Methods:
Ninety-nine patients with AD (EOAD, n=54; LOAD, n=45) and 66 cognitively normal controls completed both [18F]THK5351 and [18F]flutemetamol (FLUTE) positron emission tomography scans along with structural magnetic resonance imaging and detailed neuropsychological tests.
Results:
EOAD patients had higher THK retention in the precuneus, parietal, and frontal lobe, while LOAD patients had higher THK retention in the medial temporal lobe. Intravoxel correlation analyses revealed that EOAD presented narrower territory of local FLUTE-THK correlation, while LOAD presented broader territory of correlation extending to overall parieto-occipito-temporal regions. EOAD patients had broader brain areas which showed significant negative correlations between cortical thickness and THK retention, whereas in LOAD, only limited brain areas showed significant correlation with THK retention. In EOAD, most of the cognitive test results were correlated with THK retention. However, a few cognitive test results were correlated with THK retention in LOAD.
Conclusion
LOAD seemed to show gradual increase in tau and amyloid, and those two pathologies have association to each other. On the other hand, in EOAD, tau and amyloid may develop more abruptly and independently. These findings suggest LOAD and EOAD may have different courses of pathomechanism.
2.Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study
Junghyun NOH ; Min Kyong MOON ; Eun-Jung RHEE ; Sang Hyun PARK ; Hyeon Chang KIM ; Byung Jin KIM ; Hae Jin KIM ; Seonghoon CHOI ; Jin Oh NA ; Young Youl HYUN ; Bum Joon KIM ; Kyung-Do HAN ; In-Kyung JEONG ;
Diabetes & Metabolism Journal 2023;47(1):59-71
Background:
To validate the treatment target of low-density lipoprotein cholesterol (LDL-C) level according to the cardiovascular disease (CVD) risk which was recommended by Korean dyslipidemia guideline.
Methods:
We used the Korean National Health Insurance Service database which included 3,958,048 people aged 20 to 89 years who underwent regular health screening. The primary outcome was incident CVD, defined as a composite of myocardial infarction and stroke during the follow-up period from 2009 to 2018.
Results:
The risk of CVD increased from LDL-C level of 70 mg/dL in very high-risk and high-risk groups and from 130 mg/dL in moderate-risk and low-risk groups. Adjusted hazard ratios (HRs) of LDL-C ranges 70–99, 100–129, 130–159, 160–189, and ≥190 mg/dL were 1.20 (95% confidence interval [CI], 1.08–1.33), 1.27 (1.15–1.42), 1.39 (1.23–1.56), 1.69 (1.45–1.96), and 1.84 (1.49– 2.27) in very high-risk group, and 1.07 (1.02–1.13), 1.16 (1.10–1.21), 1.29 (1.22–1.36), 1.45 (1.36–1.55), and 1.73 (1.58–1.90) in high-risk group. Adjusted HRs (95% CI) of LDL-C ranges 130–159, 160–189, and ≥190 mg/dL were 1.15 (1.11–1.20), 1.28 (1.22– 1.34), and 1.45 (1.36–1.54) in moderate-risk group and 1.07 (1.02–1.13), 1.20 (1.13–1.26), and 1.47 (1.37–1.57) in low-risk group.
Conclusion
We confirmed the incidence of CVD was increased in higher LDL-C range. The risk of CVD increased from ≥70 mg/dL of LDL-C in very high-risk and high-risk groups, and from ≥130 mg/dL of LDL-C in moderate-risk and low-risk groups in Korean adults.
3.Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus
Min Kyong MOON ; Junghyun NOH ; Eun-Jung RHEE ; Sang Hyun PARK ; Hyeon Chang KIM ; Byung Jin KIM ; Hae Jin KIM ; Seonghoon CHOI ; Jin Oh NA ; Young Youl HYUN ; Bum Joon KIM ; Kyung-Do HAN ; In-Kyung JEONG ;
Diabetes & Metabolism Journal 2023;47(1):45-58
Background:
There are no clear data to support the cardiovascular (CV) risk categories and low-density lipoprotein cholesterol (LDL-C) treatment goals in Korean people with type 2 diabetes mellitus (T2DM). We evaluated the incidence of cardiovascular disease (CVD) according to comorbidities and suggested LDL-C treatment goals in Korean people with T2DM in nationwide cohort data.
Methods:
Using the Korean National Health Insurance Service database, 248,002 people aged 30 to 90 years with T2DM who underwent routine health check-ups during 2009 were included. Subjects with previous CVD were excluded from the study. The primary outcome was incident CVD, defined as a composite of myocardial infarction and ischemic stroke during the follow-up period from 2009 to 2018.
Results:
The mean age of the study participants was 59.6±10.9 years, and median follow-up period was 9.3 years. CVD incidence increased in the order of DM duration of 5 years or more (12.04/1,000 person-years), hypertension (HT) (12.27/1,000 personyears), three or more CV risk factors (14.10/1,000 person-years), and chronic kidney disease (18.28/1,000 person-years). The risk of incident CVD increased linearly from an LDL-C level of ≥70 mg/dL in most patients with T2DM. In T2DM patients without HT or with a DM duration of less than 5 years, the CVD incidence increased from LDL-C level of ≥100 mg/dL.
Conclusion
For primary prevention of CVD in Korean adults with T2DM, it can be helpful to lower LDL-C targets when there are chronic kidney disease, HT, a long duration of diabetes mellitus, or three or more CV risk factors.
4.Laboratory information management system for COVID-19 non-clinical efficacy trial data
Suhyeon YOON ; Hyuna NOH ; Heejin JIN ; Sungyoung LEE ; Soyul HAN ; Sung-Hee KIM ; Jiseon KIM ; Jung Seon SEO ; Jeong Jin KIM ; In Ho PARK ; Jooyeon OH ; Joon-Yong BAE ; Gee Eun LEE ; Sun-Je WOO ; Sun-Min SEO ; Na-Won KIM ; Youn Woo LEE ; Hui Jeong JANG ; Seung-Min HONG ; Se-Hee AN ; Kwang-Soo LYOO ; Minjoo YEOM ; Hanbyeul LEE ; Bud JUNG ; Sun-Woo YOON ; Jung-Ah KANG ; Sang-Hyuk SEOK ; Yu Jin LEE ; Seo Yeon KIM ; Young Been KIM ; Ji-Yeon HWANG ; Dain ON ; Soo-Yeon LIM ; Sol Pin KIM ; Ji Yun JANG ; Ho LEE ; Kyoungmi KIM ; Hyo-Jung LEE ; Hong Bin KIM ; Jun Won PARK ; Dae Gwin JEONG ; Daesub SONG ; Kang-Seuk CHOI ; Ho-Young LEE ; Yang-Kyu CHOI ; Jung-ah CHOI ; Manki SONG ; Man-Seong PARK ; Jun-Young SEO ; Ki Taek NAM ; Jeon-Soo SHIN ; Sungho WON ; Jun-Won YUN ; Je Kyung SEONG
Laboratory Animal Research 2022;38(2):119-127
Background:
As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research.
Results:
In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research.
Conclusions
This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.
5.2018 Guidelines for the Management of Dyslipidemia in Korea
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG ;
Journal of Lipid and Atherosclerosis 2019;8(2):78-131
No abstract available.
Dyslipidemias
;
Korea
6.2018 Guidelines for the management of dyslipidemia
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG
The Korean Journal of Internal Medicine 2019;34(4):723-771
7.Erratum: 2018 Guidelines for the management of dyslipidemia in Korea
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG ;
The Korean Journal of Internal Medicine 2019;34(5):1171-1171
The title and author names are incorrect.
8.The Relationship among Psychopathology, Cognitive Function, Insight and Quality of Life in Elderly Patients with Chronic Schizophrenia.
Kyungki HONG ; Joon Noh LEE ; Seon Jin YIM ; Jung Min KIM ; Euihyeon NA ; Moon Hwa HONG ; Hyeree HAN
Journal of Korean Geriatric Psychiatry 2014;18(2):55-63
OBJECTIVE: The aim of this study was to investigate the association with psychopathology, cognitive function, insight and quality of life (QOL) in elderly patients with chronic schizophrenia over age 55. METHODS: 103 schizophrenic patients over age 55 with illness duration over 10 years, are enrolled in a cross-sectional study. The subjects were assessed by the Korean version of 4th Revision of Schizophrenia Quality of Life Scale, Korean Version of Scales to Assessment Unawareness of Mental Disorder, Positive and Negative Syndrome Scale (PANSS) and the cognitive function battery designed for this study. Multiple regression stepwise selection models were executed to identify the relations among variables, and the contributing factors to QOL. RESULTS: Among schizophrenic patients with lower illness-severity with PANSS total score below 75, higher PANSS positive subscale score and lower number of hospitalization were related to lower QOL. Among patients with higher illness-severity with PANSS total score of 75 and over, higher PANSS general psychopathology subscale score, better intelligence, better delayed recall function, worse attention, better awareness of medication effect and later onset were related to lower QOL. CONCLUSION: Results of our study suggest that improvement in positive symptom and general psychopathology could increase the QOL in elderly patients with chronic schizophrenia over age 55. And the management which could improve attention, awareness of need for medication would attribute the QOL.
Aged*
;
Cognition
;
Cross-Sectional Studies
;
Hospitalization
;
Humans
;
Intelligence
;
Mental Disorders
;
Psychopathology*
;
Quality of Life*
;
Schizophrenia*
;
Weights and Measures
9.Treatment of Presumptive BK Nephropathy with Ciprofloxain in Kidney Transplant Recipients: Three Case Reports.
Hye Ran KANG ; Seong Soon KWON ; Seug Yun YOON ; Eun Na KIM ; Soon Hyo KWON ; Jin Seok JEON ; Hyunjin NOH ; Dong Cheol HAN ; So Young JIN
The Journal of the Korean Society for Transplantation 2014;28(4):254-258
BK virus nephropathy has emerged as an important cause of renal allograft dysfunction. Reduction in immunosuppression is the mainstay of BK virus nephropathy treatment. However, decreasing immunosuppressive medications is not sufficient for treatment of BK virus nephropathy. Therefore, there is a need for other treatment strategies such as cidofovir, leflunomide, and intravenous immunoglobulin in combination with immunosuppression reduction. Ciprofloxacin has recently been reported to have antiviral activity and decrease BK viral load in kidney transplant recipients. These findings suggest that the use of ciprofloxacin represents a valuable treatment strategy in patients with BK virus nephropathy. Here, we report on our experience with three patients who developed presumptive BK virus nephropathy after kidney transplantation, who, after 2 months of ciprofloxacin treatment, showed disappearance of BK viremia and improvement in the estimated glomerular filtration rate. Ciprofloxacin may be considered an effective treatment option for BK viremia in kidney transplant recipients.
Allografts
;
BK Virus
;
Ciprofloxacin
;
Glomerular Filtration Rate
;
Humans
;
Immunoglobulins
;
Immunosuppression
;
Kidney Transplantation
;
Kidney*
;
Transplantation*
;
Viral Load
;
Viremia
10.Effects of Smoking on Drinking Behavior.
Dong Hyun NOH ; Doug Hyun HAN ; Churl NA ; Kyung Joon MIN ; Doo Byung PARK
Journal of Korean Neuropsychiatric Association 2011;50(3):222-227
OBJECTIVES: This survey study was conducted to investigate the effect of smoking on drinking alcohol, depression, anxiety and impulsiveness. METHODS: The survey participants were 925 residents over 20 years of age in Gwanak-gu, Seoul. Subjects were divided into smoking and non-smoking groups, and all completed the Korean Version of the Alcohol Use Disorder Identification Test (AUDIT-K), the Beck Depression Inventory (BDI), the Barret Impulsiveness Scale (BIS) and the State-Trait Anxiety Inventory (STAI) to identify patterns of the alcohol consumption and smoking, and to assess levels of depression, anxiety and impulsiveness. RESULTS: The number of subjects with problem drinking was significantly higher in smokers (n=58, 37.2%) than non-smokers (n=81, 11.1%), and there was also a significant difference between smokers and non-smokers on the BDI. However, there were no significant differences between smokers and non-smokers on either the BIS or the STAI. When smokers with problem drinking (Smk_Alc) and smokers without problem drinking (Smk_non-Alc) were compared, the Smk_Alc subjects were found to have higher BDI and trait anxiety scores than the Smk_non-Alc group. CONCLUSION: The results of this study indicate that smoking is closely related to drinking alcohol and suggests that the more frequently people smoke, the more likely they will drink alcohol due to depression and anxiety. It may therefore important for smokers to control depressive mood, anxiety and impulsivity.
Alcohol Drinking
;
Anxiety
;
Depression
;
Drinking
;
Drinking Behavior
;
Smoke
;
Smoking

Result Analysis
Print
Save
E-mail